Questions & Answers
Partners
What kinds of partnerships does Heartgene typically pursue?
Sponsored testing programs, cohort-based research collaborations, and health system implementation. Structures are tailored to each partner's goals, regulatory context, and timeline.
How is patient consent handled?
Patients are prospectively consented at enrollment for research use of de-identified data. Consent processes and data use protocols are designed to meet IRB standards and support partner regulatory needs.
How long does it take to get started?
Most partnerships move from initial inquiry to access or onboarding within 30 to 60 days, depending on the model. Discovery and scoping typically take 2-4 weeks, with contracting and onboarding running in parallel.
Can Heartgene support prospective cohort studies or sponsor-funded testing?
Yes. Heartgene can design sponsored testing programs that enroll patients against defined genotype or phenotype criteria. Early partners have the opportunity to help shape what is collected over time.
What is the geographic reach of the program?
Testing is currently available across the United States, with nationwide genetic counseling through DNAvisit.
Who provides sequencing and interprets the results?
Sequencing is performed at Broad Clinical Labs, and variant interpretation is conducted by Mass General Brigham's Laboratory for Molecular Medicine.
Does Heartgene work with health systems that want to implement testing in their own network?
Yes. Health system partners can integrate sponsored testing into their cardiology workflow while retaining the full patient relationship and downstream clinical care. Heartgene handles ordering logistics, lab coordination, interpretation, and counseling.